Journal of the American Academy of Dermatology
Volume 60, Issue 5 , Pages e21-e22 , May 2009

Anti–tumor necrosis factor therapy and interpreting tuberculin skin tests

  • Allison J. Brown, MD

      Affiliations

    • Corresponding Author InformationCorrespondence to: Allison J. Brown, MD, Section of Dermatology, Medical College of Georgia, 1004 Chafee Ave, Augusta, GA 30912
    • ,
  • Jack L. Lesher Jr., MD

References 

  1. Doherty SD, Van Voorhees AV, Lebwohl MG, Korman NJ, Young MS, Hsu S, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59:209–217
  2. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol. 2008;59:363–380
  3. Centers for Disease Control and Prevention Web site. Division of Tuberculosis Elimination. TB facts for health care workers: identification of persons with latent TB infection and TB disease. Available at: www.cdc.gov. Accessed January 27, 2009.
  4. Centers for Disease Control and Prevention (CDC) . Tuberculosis associated with blocking agents against tumor necrosis factor alpha–California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53:683–686
  5. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1–51
  6. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;11:602–608

 Funding sources: None.

 Conflicts of interest: None declared.

PII: S0190-9622(09)00004-8

doi: 10.1016/j.jaad.2008.12.024

Journal of the American Academy of Dermatology
Volume 60, Issue 5 , Pages e21-e22 , May 2009

Article Tools